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ABSTRACT  
Objectives: The Norwegian Government urges that actions are needed to stimulate the working capacity in 
disability pensioners (DPs) with such a potential. Information on factors that may impair rehabilitation 
efforts, including use of potentially addictive drugs, may be useful in this context. Thus, the aim was to 
study the association between DP on initiation as well as long-term use of benzodiazepines (BZDs), and to 
describe aspects of problematic use of BZDs in terms of: long-term use pattern, including escalation of 
dose over time, and use of other potentially addictive drugs. 
Methods: We followed a cohort of 8,942 men and 10,578 women aged 40, 45, 60 years (non-users of 
BZDs at baseline), who participated in health surveys in 2000-01 in three Norwegian counties, with respect 
to use of BZDs, and other potentially addictive drugs, by linkage to the Norwegian Prescription Database 
(NorPD) for 2004-2007. Information on DP status was retrieved from Statistics Norway. 
Results: Incident BZD use was highest among female DPs; 18-20% compared to 5-8% of the non-DPs. 
Multivariable analyses revealed an independent effect of DP on incident (OR 1.6 (95% CI 1.4-2.0)) and 
long-term use (OR 2.47 (95% CI 1.90-3.20)) of BZDs. Among incident users, 51-60% of the DPs retrieved 
BZDs throughout the period 2004-07, as compared to 32-33% of the non-DPs. The annual median defined 
daily doses (DDDs) of BZDs among long-term users increased throughout the period 2004-07, most pro-
nounced in the youngest DPs; from 50 (interquartile range (IQR) 14,140) DDD to 205 (IQR 25,352) DDD. 
Conclusions: The chance of being prescribed BZDs as well as becoming a long-term user was higher 
among DPs. High continuation rates, with a steadily increasing annual amount of use among the long-term 
users may reflect an unfavourable use pattern of potentially addictive drugs among DPs, most worrisome 
among the youngest. 
 
 
 
INTRODUCTION 
 
Socioeconomic inequalities of health have become an 
important part of the political agenda in Norway and 
other countries1. Commonly used measures of socio-
economic status are level of education, occupation and 
level of income2. In addition; other measures of sosio-
economic status are used, such as disability pension 
which is associated with a lower educational level3. 
Equal access to and quality of health care is supposed 
to be a fundamental part of the Norwegian welfare-
system1. In this context; drugs should be prescribed 
according to medical need, irrespective of socioecono-
mic circumstances, and problematic use of potentially 
addictive drugs should be equally avoided. 
 Studies on socioeconomic inequalities in drug use 
are relatively scarce in the literature. One area high-
lighted, however, concerns socioeconomic inequalities 
in the use of statins. Statins have a well documented 
beneficial effect on cardiovascular morbidity and mor-
tality4. Thus, an inequality in statin use, due to sosio-
economic factors and not need, would imply inquality 
in the prevention of one of the leading causes of death 
in Norway. Swedish and Danish cross-sectional stu-
dies have shown a socioeconomic gradient in use of 
statins5-7. However, a recent Norwegian study showed 
that this gradient could be explained by different car-
diovascular disease (CVD) risk factor profiles (medi-
cal need) prior to the initiation of therapy, at least for 
primary CVD prevention8. In the secondary prevention 
group, however, there was a tendency to a higher statin 
use among the highly educated compared with people 
of lower educational level, after adjustment for other 
CVD risk factors, particularly in women. It may reflect 
that highly educated women may be more aware of 
their own health and new treatments than women of 
low educational level, which in turn may add up as a 
factor contributing to the observed social gradient in 
cardiovascular mortality. 
 The proportion of Norwegians on disability pen-
sions has doubled since the 1980s9. About 11 per cent 
of the working population (18-67 years) now receives 
disability benefit in Norway which constitutes both 
social and economical challenges. The Norwegian Go-
vernment has urged action to arrest the upward trend 
of people on disability pension. Information on factors 
that may impair rehabilitation efforts, including un-
favourable use of potentially addictive drugs, may be 
useful in this context. 
 In Norway, and other OECD countries, mental 
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health disorders and musculoskeletal problems are the 
main reasons for claiming disability benefit9. Benzo-
diazepines (BZDs) have anxiolytic, sedative, anti-
convulsant and muscle-relaxant effects, so they are 
likely to be used by disability pensioners to deal with 
these problems10. However, there are concerns about 
benzodiazepines because of their potential adverse 
effects, which include impaired cognitive function and 
psychomotor skills, unwanted sedation, as well as de-
pendence associated with long-term use10,11. Because 
of this, benzodiazepines are only recommended for 
short-term use over a few weeks12, and guidelines 
emphasize that combined use with other potentially 
addictive drugs, such as opioids and carisoprodol, is 
especially problematic13. Unfavorable use may be of 
particular concern in disability pensioners, as it may 
add yet another potential problem to the deterioration 
of people’s daily functioning. 
 To our knowledge, information on the use of poten-
tially addictive drugs according to disability pension 
status is scarce in the literature. However, recent stu-
dies evaluating use of potentially addictive drugs over 
a 20 year period (from 40 to 60 years of age), suggest 
that such drugs are extensively used among disability 
pensioners, and that disability pension was an inde-
pendent predictor of initiation as well as continued use 
of BZDs14,15. 
 These studies had a special focus on long-term use, 
with a 20 year period between the two measuring 
points. Thus, a limitation of these studies, was the de-
scription of use of benzodiazepines according to self-
reported disability status 20 years in the past. The pro-
portion on a disability pension increases with age; e.g. 
in 2006 about 25% of all men and 37% of all women 
aged 60 years in Norway were receivers of a disability 
pension, as compared to 1-2% of the 40-42 year old 
participants in the previous study9. Thus, an unknown 
number of the initially non-disabled 40-42 years old 
will have changed their disability status during this pe-
riod. In this situation, the OR estimates presented will 
be underestimated, and biased towards the null. 
 Also, information on long-term use was collected in 
a limited cohort of individuals, 40-42 year olds only. 
We do not know whether these findings are valid for 
other age-groups. And last, the study population con-
stituted individuals living in regions in Norway with 
above average consumption of anxiolytics and hypno-
tics over the past years, compared to other Norwegian 
regions16. Thus the trends shown in the previous stud-
ies may not be representative to other parts of Norway. 
 In this current study, we wanted to extend the 
knowledge of aspects of use of potentially addictive 
drugs to other age-groups, based on more recent data 
from regions with average overall consumption of 
these drugs. The aims of our study were to evaluate 
disability pension as a predictor of initiation and long-
term use of benzodiazepine use among individuals re-
porting to be non-users at baseline, adjusting for seve-
ral other factors that may influence use of such drugs. 
Further, other aspects of problematic use of benzodia-
zepines studied were: long-term use pattern in terms of 
percentage of incident users becoming long-term users 
and escalation of dose over time, and prevalence of 
medication with other potentially addictive drugs (z-
hypnotics, opioids and carisoprodol). 
 
 MATERIALS AND METHODS 
 
Health surveys – information on independent 
variables  
Data from Cohort of Norway (CONOR) was included 
in this study, which is a collection of health data and 
blood samples from several Norwegian health surveys 
described elsewhere17,18. CONOR data from popula-
tion based surveys conducted in 2000-01 in the three 
Norwegian counties Oslo (HUBRO and the Oslo II 
study), Hedmark and Oppland (The OPPHED study) 
are included in this study, which cover both rural and 
urban regions. Our analyses are restricted to data on 
participants aged 61 years and younger, thus including 
people below the early age of retirement (contractual 
pension) only. At the time of investigation, the sub-
jects were aged 40-41, 45-47 and 59-61 years (from 
now on referred to as two age-groups: 40+45 and 60). 
All subjects in selected age cohorts were invited to 
participate in the respective surveys. In these age 
cohorts 18,612 men and 18,273 women were invited in 
the HUBRO and OPPHED study. Of these, 9,363 men 
(50.3%) and 11,236 women (61.5%) participated and 
agreed to the storage of blood samples and data for 
research purposes and agreed to have their data linked 
to other health registers (Figure 1). In addition, our 
study-population included 46 male participants aged 
61 years from the Oslo II health study, in which the 
overall response rate was 48.7%17. 129 men and 124 
women who died or emigrated before January 1 2004 
were excluded from analyses. In a second step we 
removed all those whose drugs were reimbursed for 
treatment of cancer (Figure 1). 
 As our purpose was to study incident use of BZDs, 
BZD users at baseline were excluded. The drug use 
questions included an open question on drug trade 
names. Those who wrote trade names of benzodiaze-
pines, were excluded from our study (245 men and 442 
women). And last, persons with missing information in 
the administrative register on disability pension status 
(14 men and 6 women) were excluded resulting in a 
study-population of 19,520 people (8,942 men and 
10,578 women). 
 The participants completed a self-administered 
questionnaire covering drug use questions, history of 
diseases and risk factors, and different lifestyle habits 
such as alcohol use, smoking and physical activity and 
others. See Table 1 for details on questions and vari-
able definition. The English version of the question-
naire, as well as further details of the surveys, is 
available at the home page of the Norwegian Institute 
of Public Health18. 
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Figure 1.  Flow chart for the study population. Health surveys in Oslo, Hedmark and Oppland 2000-2001. BZD = 
benzodiazepine. 
 
 
 
 
Table 1.  Questions with answering categories and variable definition from the health surveys in Oslo, Oppland and Hedmark 2000-2001. 
 
Self-administered questionnaire Answering alternatives Variable definition 
Alcohol consumption habits    
Approximately how often during the past 12 months  Teetotaller (1); not during the last year (2);  Teetotallers/seldom =1-3;  
have you consumed alcohol? a few times the last year (3); once per month (4);  once a week-once a month =4-6;  
 2-3 times per month (5) about once a week (6) several times a week =7,8 
 2-3 times per week (7) 4-7 times per week (8)  
Smoking habits    
Did you / do you smoke daily at present? Yes (1) previously (2) no (3) smokers =1; ex-smokers= 2; non-smokers =3 
Physical activity   
Describe the physical activity in your spare-time,  Description of four levels of physical activity, seldom/never physical active =1; active =2-4 
on average during the last year. sedentary to intense, in spare time (1-4)  
Self-perceived health   
What is your current health status ? poor (1); not so good (2); good (3); very good (4) Self-perceived health not good=1,2 
Mental health problems   
Do you have or have you ever had psycholo- Yes (1)/no (2) mental health problems =1; no=2 
gical problems for which you have sought help?   
Fibromyalgia/chronic pain syndrome    
Do you have or have you ever had  Yes (1)/no (2) fibromyalgia/chronic pain syndrome =1; no=2 
fibromyalgia/chronic pain syndrome ?   
Cardiovascular history   
Do you have or have you ever had heart attack,  Yes (1) no (2) on each question CVD history =1 on either question,  
angina pectoris (heart cramp), cerebral stroke/       
brain hemorrhage    otherwise no CVD history 
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Information on disability pension status  
The variable “current activity status” from the nation-
wide population and housing census in Norway 2001 
(Statistics Norway) was used to categorize individuals 
according to disability pension status19. This variable 
is based on information from several administrative re-
gisters, and contains information on all citizens living 
in Norway. The variable categorizes Norwegian indi-
viduals according to their labour force participation; 
employed, unemployed, in education, or receipt of 
national insurance benefit (disability-, retirement- or 
survivor pension). The study population was catego-
rized as either receivers or non-receivers of a disability 
pension. 
 
Norwegian Prescription Database (NorPD) – 
information on dependent variables  
Prescription data about benzodiazepines in 2004-2007 
were drawn from the Norwegian Prescription Database 
(NorPD) which covers the entire nation (4.7 million 
inhabitants)20,21. From 1 January 2004 all the pharma-
cies in Norway became legally obliged to send in all 
electronic data on prescriptions. These returns are sent 
to the Norwegian Institute of Public Health. NorPD 
contains information of all individuals living outside 
institutions who have received prescription drugs dis-
pensed at pharmacies. All prescriptions reimbursed or 
not, are stored in the database. The drugs are classified 
according to the Anatomical Therapeutic Chemical 
(ATC) classification system22. The data collected for 
our study were patients unique identifying number 
(encrypted), sex, age, the date of dispensing, and drug 
information (brand name, package size, number of 
packages, ATC-code, Defined Daily Dose (DDDs)). 
The code of reimbursement is also recorded and this 
may function as a proxy of diagnosis. Code §9.9 is 
dedicated to cancer diseases. 
 Benzodiazepines were defined by the ATC-codes 
N05BA (anxiolytics), N05CD (hypnotics) and 
N03AE01 (clonazepam), benzodiazepine-like drugs 
(z-hypnotics; zolpidem and zopiclone) by the ATC-
code N05CF, opioids by the ATC-code N02A and 
carisoprodol by the ATC-code M01BA02. Incident use 
was defined when an individual (non-user at baseline) 
was dispensed at least one prescription of a 
benzodiazepine during the period 1 January 2004 – 31 
December 2004. Long-term use was defined when an 
individual (non-user at baseline) was dispensed at least 
one prescription of a benzodiazepine each of the years 
2004 to 2007. Among BZD users in 2004, the propor-
tion of long-term users throughout the period 2004-07 
was calculated, according to disability pension status 
and age. 
 In addition, among the long-term benzodiazepine 
users, the annual amount of BZDs dispensed in the 
period 2004-2007 was calculated in terms of total de-
fined daily doses (DDDs). 
 A DDD in clinical practice is defined as the 
assumed average maintenance dose per day for a drug 
used on its main indication in adults23. The DDDs for 
the benzodiazepines registered in Norway, and inclu-
ded in our analysis, are as follows; diazepam 10 mg, 
oxazepam 50 mg, alprazolam 1 mg, nitrazepam 5 mg, 
flunitrazepam 1 mg, midazolam 15 mg, clonazepam 8 
mg. Data from the health surveys, administrative re-
gister and NorPD were linked based on the unique 
encrypted identification number. 
 
Statistics  
Chi-square test was used to assess equality of propor-
tions across the groups of drug use. Mann-Whitney 
test was used for variables with a skewed distribution 
(DDDs, presented as median and interquartile ranges 
(IQR)). Association between disability pension status 
and others factors with incident BZD use in 2004 and 
long-term BZD use (2004-07) was estimated by logis-
tic regression, and presented as crude and adjusted 
odds ratios (ORs) with 95% confidence intervals (CI). 
All analyses were done using SPSS 17.0 for Windows. 
Level of significance was set to p<0.05. 
 
Ethical considerations  
The study protocol was assessed by the Regional Com-
mittee for Medical Research Ethics and approved by 
the Norwegian Data Inspectorate. 
 
 
RESULTS 
 
Baseline characteristics (non-users of 
benzodiazepines)  
Characteristics of the study population, non-users of 
benzodiazepines at baseline, are shown in Table 2. 
There was a higher prevalence of teetotallers and 
current daily smokers among disability pensioners. 
Further, there was a higher proportion of unmarried 
people (except in 60 year old women) and physically 
inactive persons (except in 60 year old men) among 
receivers of a disability pension. 
 About 2/3 of the disability pensioners reported poor 
self-perceived health at baseline, irrespective of age 
and gender. Also, the prevalences of mental health 
problems, fibromyalgia/chronic pain syndrome and 
cardiovascular disease were significantly higher 
among receivers of a disability pension. 
 Self-reported use of z-hypnotics, opioids and 
carisoprodol at baseline were higher among disability 
pensioners, except for z-hypnotics in 60-year old men. 
 
Retrieval of prescription drugs in 2004 and 2004-
2007  
In both genders, and irrespective of age, incident BZD 
use 3-4 years later was significantly higher among dis-
ability pensioners (Table 2). Highest initiation rates 
were observed among female disability pensioners, of 
whom 18-20% had started BZDs, as compared to 5-
8% of the female non-receivers of a disability pension 
at baseline. 
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Table 2.  Prevalence (n (%)) of baseline characteristics among men and women who were nonusers of benzodiazepines when surveyed in 
2000-01. Use of prescription drugs retrieved from the Norwegian Prescription Database in 2004-2007 according to baseline characteristics. 
 
 40+45 years  60 years 
  Men   Women  Men   Women 
  Disability pension (2001)     Disability pension (2001)    Disability pension (2001)     Disability pension (2001)   
 
Yes 
(N=167) 
No 
(N=5735) p  
Yes 
(N=268) 
No 
(N=7059) p  
Yes 
(N=483) 
No 
(N=2557) p  
Yes 
(N=674) 
No 
(N=2577) p 
Baseline characteristics 2000-01                
Unmarried  107 (65.2) 2226 (38.8) <0.000  156 (58.2) 2725 (38.6) <0.000  188 (38.9) 701 (27.4) <0.000  255 (37.8) 919 (35.7) 0.296 
Alcohol habits                 
     Teetotallers/seldom 66 (41.3) 1037 (18.3)   142 (54.0) 1718 (24.6)   156 (33.3) 451 (17.8)   323 (48.5) 746 (29.3)  
     Once a week-once a month 71 (44.4) 3202 (56.4)   92 (35.0) 3927 (56.2)   216 (46.1) 1170 (46.1)   255 (38.3) 1197 (46.9)  
     Several times a week 23 (14.4) 1435 (23.3) <0.000  29 (11.0) 1341 (19.2) <0.000  97 (20.7) 918 (36.2) <0.000  88 (13.2) 607 (23.8) <0.000 
Smoking habits                
     Current daily smokers  87 (52.1) 1755 (30.6)   129 (48.1) 2323 (32.9)   188 (38.9) 584 (22.8)   221 (32.8) 531 (20.6)  
     Exsmokers  30 (18.0) 1474 (25.7)   53 (19.8) 1856 (26.3)   174 (36.0) 1040 (40.7)   177 (26.3) 699 (27.1)  
     Non smokers 50 (29.9) 2506 (43.7) <0.000  86 (32.1) 2880 (40.8) <0.000  121 (25.1 ) 933 (36.5) <0.000  276 (40.9) 1347 (52.3) <0.000 
Seldom/never physical active 61 (39.4) 1392 (25.1) <0.000  79 (31.7) 1332 (19.5) <0.000  102 (22.6) 484 (19.4) 0.123  195 (29.8) 522 (21.0) <0.000 
Self-perceived health (not good) 117 (72.7) 966 (17.0) <0.000  180 (68.7) 1310 (18.8) <0.000  315 (66.2) 556 (22.0) <0.000  448 (67.2) 698 (27.5) <0.000 
Mental health problemsa 74 (44.3) 587 (10.2) <0.000  119 (44.4) 1157 (16.4) <0.000  109 (22.6) 212 (8.3) <0.000  175 (26.0) 322 (12.5) <0.000 
Fibromyalgia/chronic pain 
syndrome 27 (16.2) 150 (2.6) <0.000  91 (34.7) 472 (6.7) <0.000  53 (11.0) 65 (2.5) <0.000  255 (37.8) 265 (10.3) <0.000 
Cardiovascular history 17 (10.2) 110 (1.9) <0.000  11 (4.1) 46 (0.7) <0.000  134 (27.7) 249 (9.7) <0.000  79 (11.7) 95 (3.7) <0.000 
Drug use at baseline (selfreport)                
     z-hypnotics 5 (3.0) 65 (1.1) 0.029  21 (7.8) 139 (2.0) <0.000  7 (1.4) 40 (1.6) 0.851  52 (7.7) 102 (4.0) <0.000 
     opioids 25 (15.0) 177 (3.1) <0.000  47 (17.5) 277 (3.9) <0.000  51 (10.6) 65 (2.5) <0.000  78 (11.6) 101 (3.9) <0.000 
     carisoprodol 6 (3.6) 28 (0.5) <0.000  14 (5.2) 78 (1.1) <0.000  7 (1.4) 6 (0.2) 0.002  19 (2.8) 16 (0.6) <0.000 
NorPD 2004b                
     benzodiazepines 22 (13.2) 173 (3.0) <0.000  53 (19.8) 384 (5.4) <0.000  53 (11.0) 109 (4.3) <0.000  121 (18.0) 214 (8.3) <0.000 
          DDD (IQR) among users  73 (25,196) 20 (10,65) <0.000  40 (14,116) 15 (9,38) <0.000  50 (18,178) 20 (10,50) <0.000  50 (20,150) 18 (10,50) <0.000 
     z-hypnotics 18 (10.8) 243 (4.2) <0.000  55 (20.5) 508 (7.2) <0.000  49 (10.1) 184 (7.2) 0.025  138 (20.5) 346 (13.4) <0.000 
     opioids 35 (21.0) 537 (9.4) <0.000  71 (26.5) 712 (10.1) <0.000  89 (18.4) 286 (11.2) <0.000  164 (24.3) 320 (12.4) <0.000 
     carisoprodol 10 (6.0) 135 (2.4) 0.009  30 (11.2) 276 (3.9) <0.000  15 (3.1) 34 (1.3) 0.004  41 (6.1) 63 (2.4) <0.000 
NorPD 2004-07c                
      benzodiazepines 9 (5.4) 59 (1.0) <0.000   29 (10.8) 117 (1.7) <0.000   29 (6.0) 32 (1.3) <0.000   76 (11.3) 74 (2.9) <0.000 
*p-value<0.05; **p-value<0.01; ***p-value<0.001; n.s., not significant         
a Sought help for mental health problems         
b use was defined as retrieveal of at least 1 prescription in 2004         
c long-term use was defined as retrieveal of at least 1 prescription in 2004, 2005, 2006 and 2007         
 
 
 
 
 Prevalence of use of all other potentially addictive 
substances, such as z-hypnotics, opioids and carisopro-
dol had increased 3-4 years later, irrespective of age, 
gender and disability pension status at baseline. E.g. in 
2004, 18-27% of disability pensioners retrieved a pre-
scription on an opiod, about twice the level of retrieval 
among the non-receivers of a disability pension. 
 A significantly higher proportion of the disability 
pensioners became long-term users of benzodiazepines 
as compared to the non-receivers of a disability pen-
sion, 5-6% of the male and 10-11% of the female dis-
ability pensioners. 
 
Predictors of BZD use  
Univariate and adjusted ORs for incident retrieval of 
benzodiazepine prescription were higher among dis-
ability pensioners, as compared with those registered 
as non-receivers of a disability pension 3-4 years in the 
past (Table 3). 
 Further, univariate OR for long-term use of benzo-
diazepines was above six times higher among the 
receivers compared to the non-receivers of a disability 
pensioners (Table 3). After adjustment for age, sex, 
lifestyle, physical and mental health, and socio-
economic variables the OR was lowered to 2.5 (1.9-
3.2). Other independent predictors of long-term BZD 
use were; increasing age, female gender, an unmarried 
status, previous smoking, physical inactivity, poor 
self-perceived health, fibromyalgia/chronic pain syn-
drome and a CVD history. The strongest predictor of 
long-term BZD use was self-reported mental health 
problems at baseline. 
 
Patterns of long-term BZD use, and amount of use 
among the long-term BZD users  
The proportion of incident BZD users in 2004 who 
continued to retrieve BZD prescriptions throughout the 
period 2004-07 was higher among receivers compared 
to the non-receivers of a disability pension at baseline 
(Figure 2). Among BZD users in 2004, half of the 
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Table 3.  Number (n) and proportion (%) of incident (2004) and long-term (2004-07) BZD use among participants in population based 
studies 2000-2001, non-users of BZD at baseline (8,942 men and 10,578 women). Association between disability pension status and 
others factors with incident (2004) and long-term (2004-07) BZD use; unadjusted and adjusted odds ratio (OR) with 95% confidence 
interval (CI). 
         
    Incident BZD 2004                  Long-term BZD user (2004-07) 
  In the model    In the model  
 n (%) 
Unajusted OR 
(95%CI) 
Adjusted* OR 
(95%CI)  n (%) 
Unajusted OR 
(95%CI) 
Adjusted* OR 
(95%CI) 
Disability pension        
     No 880 (4.9) 1.0 (referent) 1.0 (referent)  282 (1.6) 1.0 (referent) 1.0 (referent) 
     Yes 249 (15.6) 3.59 (3.01-4.18) 1.64 (1.36-1.97)  143 (9.0) 6.18(5.02-7.61) 2.47 (1.90-3.20) 
Age         
     40+45 632 (4.8) 1.0 (referent) 1.0 (referent)  214 (1.6) 1.0 (referent) 1.0 (referent) 
     60 498 (7.9) 1.71 (1.52-1.94) 1.56 (1.36-1.79)  211 (3.4) 2.11 (1.74-2.56) 1.72 (1.37-2.15) 
Sex         
     Men 358 (4.0) 1.0 (referent) 1.0 (referent)  129 (1.4) 1.0 (referent) 1.0 (referent) 
     Women 772 (7.3) 1.89 (1.66-2.15) 1.82 (1.58-2.10)  296 (2.8) 1.97 (1.60-2.43) 1.81 (1.44-2.27) 
Unmarried        
     No 601 (4.9) 1.0 (referent) 1.0 (referent)  202 (1.6) 1.0 (referent) 1.0 (referent) 
     Yes 527 (7.2) 1.51 (1.34-1.71) 1.20 (1.05-1.36)  223 (3.1) 1.88 (1.55-2.83) 1.39 (1.13-1.72) 
Alcohol        
     Teetotallers/seldom 316 (6.8) 1.0 (referent) 1.0 (referent)  118 (2.5) 1.0 (referent) 1.0 (referent) 
     Once a week-once a month 547 (5.4) 0.81 (0.68-0.96) 1.07 (0.89-1.29)  205 (2.0) 0.87 (0.62-1.08) 1.17 (0.87-1.58) 
     Several times a week 253 (5.6) 0.78 (0.68-0.90) 1.04 (0.89-1.21)    95 (2.1) 0.79 (0.63-1.00) 1.18 (0.92-1.51) 
Smoking        
     Non-smokers 362 (4.4) 1.0 (referent) 1.0 (referent)  116 (1.4) 1.0 (referent) 1.0 (referent) 
     Exsmokers  295 (5.4) 1.91 (1.66-2.21) 1.73 (1.49-2.02)  105 (1.9) 2.53 (2.01-3.19) 2.16 (1.68-2.78) 
     Current daily smokers  473 (8.1) 1.23 (1.05-1.44) 1.18 (1.00-1.40)  204 (3.5) 1.36 (1.04-1.77) 1.33 (1.00-1.76) 
Seldom/never physical active        
     No 777 (5.3) 1.0 (referent) 1.0 (referent)  277 (1.9) 1.0 (referent) 1.0 (referent) 
     Yes 313 (7.5) 1.45 (1.27-1.67) 1.29 (1.12-1.49)  132 (3.2) 1.70 (1.38-2.10) 1.41 (1.13-1.76) 
Self-perceived health (not good)        
     No 631 (4.3) 1.0 (referent) 1.0 (referent)  196 (1.3) 1.0 (referent) 1.0 (referent) 
     Yes 487 (10.6) 2.65 (2.34-2.99) 1.57 (1.36-1.82)  224 (4.9) 3.79 (3.12-4.61) 1.78 (1.41-2.43) 
Mental health problems        
     No 731 (4.4) 1.0 (referent) 1.0 (referent)  245 (1.5) 1.0 (referent) 1.0 (referent) 
     Yes 399 (14.5) 3.71 (3.26-4.22) 2.85 (2.47-3.28)  179 (6.5) 4.66 (3.83) 3.21 (2.58-9.98) 
Fibromyalgia/chronic pain syndrome        
     No 944 (5.2) 1.0 (referent) 1.0 (referent)  336 (1.9) 1.0 (referent) 1.0 (referent) 
     Yes 186 (13.4) 2.83 (2.39-3.45) 1.31 (1.08-1.60)  89 (6.4) 3.65 (2.87-4.64) 1.31 (0.98-1.74) 
Cardiovascular disease history        
     No 1050 (5.6) 1.0 (referent) 1.0 (referent)  387 (2.1) 1.0 (referent) 1.0 (referent) 
     Yes 80 (10.8) 2.04 (1.60-2.59) 1.47 (1.13-1.93)  38 (5.1) 2.56 (1.87-3.60) 1.54 (1.05-2.25)                 
*Adjusted for all variables in Table 
 
 
 
 
youngest (40+45 years at baseline) and 60% of the 
oldest (60 years at baseline) continued to retrieve 
benzodiazepines throughout the period 2004-07, as 
compared to a third of the non-receivers of a disability 
pension (Figure 2). 
 Among long-term users, the median amount of 
BZDs retrieved among disability pensioners in 2004 
was 50 DDD, as compared to 18-20 DDD among the 
non-receivers of a disability pension (Figure 3). The 
annual median DDD of benzodiazepines among con-
tinued users increased steadily throughout the period, 
most pronounced among the youngest disability pen-
sioners. 
DISCUSSION 
 
In a study-population reporting to be non-users of 
BZDs at baseline; the proportion of disability pensio-
ners that had started benzodiazepines 3-4 years later 
were about fourfold among 40+45 year old and about 
doubled in the 60 year old compared to those registe-
red as non-receivers of a disability pension at baseline. 
Further, once started BZD use in 2004, continuation 
rates were high, with a steadily increasing amount of 
BZDs (DDDs) throughout the period 2004-2007. 
 A higher use of benzodiazepine use among those re-
gistered as disability pensioners may partly be explai-
USE OF POTENTIALLY ADDICTIVE DRUGS AMONG DISABILITY PENSIONERS 215 
 
Figure 2.  Proportion of long-term use of benzodiazepines among users (men and women) in 2004, 
throughout the period 2004-07, according to disability pension status and age. DP = disability pensioners. 
 
 2004 2005 2006 2007 
DP-status (age) n (%) n (%) n (%) n (%) 
+ DP (40+45)   75 (100)   56 (74.7)   46 (61.3)   38 (50.7) 
– DP (40+45) 557 (100) 292 (52.4) 221 (39.7) 176 (31.6) 
+ DP (60) 174 (100) 138 (79.3) 119 (68.3) 105 (60.3) 
– DP (60) 323 (100) 170 (52.6) 135 (41.8) 106 (32.8) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  Median amount (DDDs with interquartile range (IQR)) of benzodiazepines retrieved among long-term users (men 
and women) throughout the period 2004-2007, according to age and disability pension status. DP= disability pensioners. 
 
 2004 2005 2006 2007 
DP status (age) DDD (IQR) DDD (IQR) DDD (IQR) DDD (IQR) 
+ DP (40+45) 50 (15,140) 78 (29, 220) 116 (49, 116) 205 (25, 352) 
– DP (40+45)   18 (10,50) 35 (13, 100)   50 (20, 120)   51 (21, 150) 
+ DP (60) 50 (20,150) 81 (29, 200)   75 (30, 170)   90 (48, 200) 
– DP (60)   20 (10,50) 50 (15, 100)   50 (20, 125)   50 (25, 150) 
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ned by a higher prevalence of mental health symptoms 
in this group at baseline. Mental health problems are 
the main reason for being granted a disability pension 
in Norway, in young people in particular24. Thus, 
mental health problems were the strongest predictor of 
incident and long-term BZD use, and almost half of all 
40+45 year old disability pensioners in our study were 
registered as receivers of a disability pension. Still, 
however, adjustment for various confounders, inclu-
ding self-perceived health and self-reported presence 
of mental health problems at baseline, revealed an in-
dependent effect of disability pension on the initiation 
and thereby long-term use of benzodiazepines 3-4 
years later. Our study supports that initiation and long-
term use of BZDs may be attributed to the DP situation 
which itself may bring about a number of psychologi-
cal problems as a result of exclusion from the social 
and personal advantages associated with being a part 
of the workforce25. Drug treatment with benzodiaze-
pines may be initiated to relieve these symptoms. Our 
evaluation of disability pension as a risk-factor of 
benzodiazepine use must, however, be interpreted with 
caution. Even if many potential confounders associa-
ted with prescription of benzodiazepines were registe-
red and adjusted for in our analysis, all possible con-
founders may not have been taken into account. Our 
observations of an independent effect of disability 
pension on the initiation and long-term use of BZDs, 
however, are in agreement with a previous study eva-
luating incident benzodiazepine-taking behaviour over 
a 20 year span14,15. 
 Because of concerns related to the potential side-
effects, such as impaired cognitive function and 
psychomotor skills, and addiction problems10,11, ben-
zodiazepines are only recommended for short-term use 
over a few weeks12. Still 50-60 per cent of those dis-
ability pensioners who retrieved a BZD prescription in 
2004 continued to retrieve BZD prescriptions through-
out the period 2004-2007. Parallel continuation rates 
were observed over a 20-year period in a previous 
study; more than half of those on disability pensions 
continued to receive benzodiazepine prescriptions 20 
years later, a span covering a large part of the potential 
active workforce period14. Our findings add to obser-
vations in other studies on long-term use; having once 
entered a cohort of benzodiazepine users, the probabi-
lity of still being part of that cohort in the following 
years is consistently high in different populations26-28. 
Thus, in this context, high initiation rates among the 
youngest disability pensioners observed in our study 
may perhaps be most worrisome. Once started, larger 
proportions will most likely continue to use BZDs 
throughout their potential work-force period. 
 One could argue that one annual prescription over a 
4 year period is neither an outcome for long-term use, 
nor an addictive use pattern. However, the observed 
annual increase in amount of benzodiazepines dis-
pensed over this 4-year period indicates more than 
sporadic use, among the youngest disability pensioners 
(40+45 years) in particular. In 2004 half of the youn-
gest disability pensioners were dispensed an annual 
amount of benzodiazepines corresponding to the use of 
a daily dose every week (median 50 daily doses), in-
creasing to retrieval of a daily dose every second day 
in 2007 (median 205 daily doses). A corresponding 
amount, a dose every second day, was observed in the 
previous study evaluating continued use of benzo-
diazepines over a 20-year period14. In addition, and 
relevant to the discussion of unfavourable use of po-
tentially addictive drugs, baseline level (2000-2001) of 
use of all other potentially addictive substances, such 
as z-hypnotics, opioids and carisoprodol had increased 
3-4 years later in disability pensioners, irrespective of 
age and gender. Parallel, as revealed in our previous 
study, the majority of those who were still dispensed 
benzodiazepines 20 years later, were also dispensed 
opioids; half of all men and 3 out of four women. 15-
20% retrieved benzodiazepines combined with both 
opioids and carisoprodol14. Guidelines emphasize that 
combined use with other potentially addictive drugs, 
such as opioids and carisoprodol, is especially proble-
matic12,13. These recommendations are being violated 
when continued and combined use of benzodiazepines 
exists to the extent observed in our present and pre-
vious studies. Unfavourable use may be of particular 
concern in disability pensioners, as it may add yet an-
other potential problem to the deterioration of people’s 
daily functioning, help consolidate the disability situ-
ation. 
 As in previous studies, in the present study we 
chose to focus on use of traditional benzodiazepines, 
with its well known potential of causing addiction 
problems and other negative effects interfering with 
people’s daily functioning10,11. Thus, we excluded pre-
scriptions on benzodiazepine-like hypnotics from our 
analysis. In Norway benzodiazepine-like hypnotics, z-
hypnotics, are now recommended as first-choice 
hypnotics for short-term use in severe insomnia. These 
substances, zopiclone in particular, are the most com-
monly used hypnotics in Norway. Hence, 85-90% of 
all individuals who retrieved at least one prescription 
on a hypnotic in Oslo, Hedmark and Oppland were 
users of benzodiazepine-like hypnotics in 200721. Re-
cent literature, however, adds to the growing evidence 
that these substances have a similar potential for nega-
tive effects as traditional benzodiazepines29-31. Still we 
wanted to restrict our analysis to the prescription of the 
traditional benzodiazepines, which constitutes a better 
documented marker of an addictive use pattern29,32,33. 
 This study is prospective with information from 
nationwide registers on exposure (disability pension 
status) and outcome (BZDs) variables. However, our 
study-population is attendants in health surveys, in 
which attendance rates at 50-60% may imply a risk of 
selection bias. Unfortunately we do not have informa-
tion on all non-attendants in our study. However, an 
evaluation of the non-attendees in the Oslo Health 
Survey (HUBRO) was performed; receivers of a dis-
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ability pension were over-represented among the non-
attendees, while some health indicators, including 
mental health (HSCL), probably did not differ34. Low 
attendance may bias the representativity of baseline 
characteristics or prevalences, but is less likely to in-
fluence estimates of associations such as odds ratios. 
Further, self-reported use of BZD at baseline may be 
underreported. In general, anxiolytics and hypnotics/ 
sedatives are prone to be underreported, possibly due 
to the stigma of mental health problems35. Thus, there 
may be an unknown number of BZD users at baseline 
included in our study-population. 
 In conclusion, compared to previous studies which 
had a special focus on incident and long-term use of 
benzodiazepines over a 20-year period, this study adds 
complementary and new information of aspects of use 
of potentially addictive drugs among disability pensio-
ners in Norway. Our study suggests that BZDs, and 
other potentially addictive drugs, are extensively used 
among disability pensioners, and that disability pen-
sion may have an independent effect on initiation fol-
lowed by long-term use of BZDs. Once started, rates 
of continued retrieval of BZDs are high, with a steadi-
ly increasing annual amount of use, most pronounced 
among the youngest disability pensioners. Efforts to 
bring those with potential to work back into employ-
ment have been a part of the political agenda for the 
last decade. Improved management of BZD use may 
be one part of this effort. 
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